Late phase transfusion after CAR T therapy is associated with…
Identifying which multiple myeloma patients need transfusions late after CAR-T therapy could help doctors spot those at highest risk and intervene earlier.
- Lab
- Preclinical
- Early trials
- Late trials
- In practice
Dual-target CAR-T cell therapy
Newer CAR-T designs targeting two cancer markers simultaneously show promise across blood cancers and autoimmune conditions, potentially overcoming limitations of single-target approaches.
Standard additionHeterogeneity in proportional cardiovascular co-listing on cancer…
Tracking how often heart disease appears alongside cancer deaths reveals we may be undercounting treatment-related heart harm, enabling better long-term safety monitoring.
Near-term implementable findingThree-Dimensional Portal Vein Geometry Predicts Post-TIPS Hepatic…
Simple 3D scans of liver blood vessels before a procedure can now predict which cirrhosis patients will develop serious complications, improving surgical planning.
Promising but preliminaryMolecular characteristics for poor prognosis related renal cell…
Genetic testing of kidney cancer tissue reveals which patients have aggressive tumors earlier, potentially guiding more aggressive upfront treatment decisions.